ESMO 2023 | Trastuzumab deruxtecan in patients with breast cancer with brain metastases

Janice Wing-Hang Tsang, MBBS, MRCP, FRCP, University of Hong Kong, Hong Kong, China, discusses findings a pooled analysis of the DESTINY-Breast01, -02, and -03 trials (NCT03248492, NCT03523585, NCT03529110), which assessed trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate, in patients with breast cancer and brain metastases. T-DXd resulted in robust intracranial response rates, especially in patients with untreated brain metastases. Additional studies are needed to demonstrate clinical benefit and overall survival. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.